ClinicalTrials.gg
Not yet recruitingNCT07577986Updated May 11, 2026

A Safety and Efficacy Trial of Chidamide Combined With NKG2D CAR-NK Cell Therapy for Reducing the HIV Viral Reservoir

A Phase 1/2 interventional study of Chidamide Combined with NKG2D CAR-NK Cell Therapy in HIV (Human Immunodeficiency Virus), sponsored by First Affiliated Hospital of Zhejiang University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by First Affiliated Hospital of Zhejiang University · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study aims to investigate the safety and preliminary efficacy of an innovative therapeutic strategy combining chidamide with NKG2D-directed chimeric antigen receptor natural killer (CAR-NK) cells in individuals living with HIV. The approach is predicated on the "shock and kill" paradigm: chidamide is employed to reactivate latent HIV reservoirs and upregulate surface target ligands (NKG2D ligands) on infected cells; subsequently, allogeneic NKG2D CAR-NK cells are infused to specifically recognize and eliminate these "marked" cells.

This is a phase I, open-label, single-arm clinical trial comprising two distinct stages: a dose-escalation phase (phase Ia, utilizing a "1+3+3" design) and a dose-expansion phase (phase Ib). A total of 20 HIV-infected individuals who are stable on antiretroviral therapy (ART) and have suppressed plasma viremia are planned for enrollment. Participants will receive oral chidamide over approximately five weeks, followed by two cycles of intravenous CAR-NK cell infusion.

The primary endpoint is the safety and tolerability of the regimen, with particular attention to immune-related adverse events including cytokine release syndrome (CRS). Secondary endpoints encompass exploratory assessments of potential virologic and immunologic effects, such as alterations in plasma HIV RNA, cell-associated viral nucleic acids, and CD4+ T-cell counts. This study is intended to provide initial human safety data and preliminary evidence regarding the potential of this combination strategy to contribute toward a functional cure for HIV infection.

Read the detailed description

Background and Rationale:

Currently, highly active antiretroviral therapy (HAART) effectively suppresses HIV replication; however, it fails to eradicate the latent viral reservoir, necessitating lifelong pharmacotherapy for infected individuals. This study is predicated on the "shock and kill" strategy and combines the histone deacetylase inhibitor chidamide with allogeneic chimeric antigen receptor natural killer (CAR-NK) cells targeting NKG2D ligands, aiming to explore a novel potential approach toward a functional cure for HIV infection. Preclinical investigations have demonstrated that chidamide not only reactivates latent virus but also upregulates the expression of NKG2D ligands on the surface of infected cells, while NKG2D CAR-NK cells exhibit specific recognition and elimination of such target cells, thereby establishing a clear synergistic effect between the two modalities.

Study Objectives:

Primary Objective: To evaluate the safety and tolerability of the combined therapeutic regimen in HIV-infected individuals receiving stable antiretroviral therapy.

Secondary Objectives: To preliminarily explore the impact of this regimen on virologic and immunologic parameters, including plasma HIV RNA, cell-associated viral nucleic acids, and CD4⁺ T-cell counts.

Study Design:

This is a prospective, open-label, single-arm, phase I clinical trial comprising dose-escalation and dose-expansion stages. The study is conducted in two distinct phases:

Phase Ia (Dose Escalation): A modified "1+3+3" design will be employed to evaluate the safety of three dose levels of CAR-NK cells (DL1: 5×10⁸, DL2: 1×10⁹, DL3: 2×10⁹ cells per infusion) and to determine the recommended phase II dose (RP2D). The dose-limiting toxicity (DLT) observation period is defined as 28 days following the initial cell infusion.

Phase Ib (Dose Expansion): An expansion cohort will be enrolled at the established RP2D to further assess safety and preliminary efficacy.

Study Participants:

A total of 20 HIV-infected individuals are planned for enrollment, meeting the following eligibility criteria: age 18-65 years, receipt of antiretroviral therapy (ART) for a minimum of two years, sustained virologic suppression (plasma HIV RNA \<50 copies/mL), CD4⁺ T-cell count >200 cells/μL, and compliance with additional health-related inclusion criteria.

Intervention:

All enrolled participants will receive oral chidamide (10 mg twice weekly) for approximately five weeks. During this period, participants will receive two cycles of intravenous infusion of allogeneic NKG2D CAR-NK cells (each cycle consisting of two consecutive daily infusions, separated by an interval of approximately two weeks). Throughout the treatment course, participants will continue their pre-existing antiretroviral regimen without modification.

Figure 1. Schematic Diagram of Participant Follow-Up and Study Procedures

Outcome Measures:

Safety Endpoints: Incidence and characterization of adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs), with particular emphasis on cytokine release syndrome (CRS) and neurotoxicity.

Exploratory Efficacy Endpoints: Dynamic changes in plasma HIV RNA, cell-associated HIV RNA/DNA, and CD4⁺/CD8⁺ T-cell counts from baseline to post-treatment assessments.

Additional Exploratory Endpoints: In vivo expansion and persistence of CAR-NK cells (pharmacokinetics, PK), cytokine profiling, and alterations in senescence-associated biomarkers.

Significance of the Study:

This study represents the first-in-human evaluation of the safety profile of chidamide in combination with allogeneic NKG2D CAR-NK cell therapy in the context of HIV infection. Furthermore, it will provide preliminary clinical evidence regarding the potential of this combinatorial strategy to reduce the viral reservoir, thereby potentially opening new avenues for the development of functional cure strategies for HIV infection.

02

Conditions studied

  • HIV (Human Immunodeficiency Virus)

Browse trials for

Keywords

  • HIV
  • CAR-NK
  • Functional cure
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's planned enrollment of 20 is below the median of 96 across 2,254 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

First Affiliated Hospital of Zhejiang University is the lead sponsor of 264 studies on the registry; 145 are open to participants now.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A participant will be deemed eligible for enrollment only if all of the following criteria are met:

  1. Diagnosis of infection, with a current history of highly active antiretroviral therapy (HAART) for a minimum duration of two years.
  2. Age between 18 and 65 years, inclusive.
  3. Plasma HIV RNA level \< 50 copies/mL (virologic suppression).
  4. CD4⁺ T cell count > 200 cells/μL.
  5. Adequate hematologic function defined as:

    • ≥ 90 g/L;
    • count ≥ 75 × 10⁹/L;
    • (ANC) ≥ 1.0 × 10⁹/L;
    • White blood cell count ≥ 2 × 10⁹/L.
  6. Adequate hepatic and renal function defined as:

    • Serum creatinine ≤ 1.5 × (ULN);
    • (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN;
    • Total ≤ 2 × ULN;
    • (PT) prolongation \< 3 seconds.
  7. Hemodynamically stable with a (LVEF) ≥ 45%.
  8. Negative serum or urine pregnancy test for females of .
  9. Willingness of the participant to:

    • Practice effective during the study period and for one year following completion of the trial;
    • Voluntarily provide written and comply with scheduled follow up visits and study procedures.

Exclusion criteria

Exclusion Criteria

Participants meeting any of the following criteria will be excluded from study participation:

  1. Presence of severe cardiovascular, respiratory, or hematologic disease; active infectious disease (other than controlled infection); or active .
  2. Positive serology for surface antigen (HBsAg) or detectable virus RNA (HCV RNA).
  3. Diagnosis of chronic kidney disease (CKD).
  4. History or presence of acute or chronic pancreatitis.
  5. Active severe peptic ulcer disease.
  6. Current severe neurologic or psychiatric disorder.
  7. History of alcohol abuse or illicit substance use disorder.
  8. Known allergic diathesis or to any component of the agents.
  9. Female participants who are pregnant, lactating, or of and unwilling to adhere to required measures.
  10. Concurrent use of agents.
  11. Any other condition that, in the opinion of the investigator, renders the participant unsuitable for study participation.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Chidamide Combined with NKG2D CAR-NK Cell Therapy

    All enrolled participants will receive oral chidamide (10 mg twice weekly) for approximately five weeks. During this period, participants will receive two cycles of intravenous infusion of allogeneic NKG2D CAR-NK cells (each cycle consisting of two consecutive daily infusions, separated by an interval of approximately two weeks). Throughout the treatment course, participants will continue their pre-existing antiretroviral regimen without modification.

    Drug: Chidamide Combined with NKG2D CAR-NK Cell Therapy

Interventions

  • DrugChidamide Combined with NKG2D CAR-NK Cell Therapy

    All enrolled participants will receive oral chidamide (10 mg twice weekly) for approximately five weeks. During this period, participants will receive two cycles of intravenous infusion of allogeneic NKG2D CAR-NK cells (each cycle consisting of two consecutive daily infusions, separated by an interval of approximately two weeks). Throughout the treatment course, participants will continue their pre-existing antiretroviral regimen without modification.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Study Drug-Related Adverse Events Grade 3 or Higher

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of the study drug as either having a reasonable possibility or no reasonable possibility. AEs are given a grade from 1-5 with Grade 3 being severe but not life-threatening and requiring hospitalization, Grade 4 being life-threatening requiring immediate intervention and Grade 5 being death related to an AE.

    Time frame: From enrollment to the end of treatment at 24 weeks

  2. Number of Participants with Study Drug-Related Immune-Related Adverse Events (IRAE)

    Assessed using the American Society of Clinical Oncology (ASCO) IRAE management guidelines (which utilizes the NIH CTCAE grading scale) but modified, as applicable, according to the NIH Division of AIDS (DAIDS) (v2.1) AE grading scale

    Time frame: From enrollment to the end of treatment at 24 weeks

  3. Number of Participants with Adverse Events (AEs) Corresponding to Cytokine Release Syndrome

    Adverse Events (AEs) Corresponding to Cytokine Release Syndrome

    Time frame: From enrollment to the end of treatment at 24 weeks

Secondary outcomes

  1. Changes in the HIV latent reservoir

    Dynamic changes in plasma HIV RNA, HIV DNA and HIV cell-associated RNA

    Time frame: From enrollment to the end of treatment at 24 weeks

  2. Change in T-lymphocyte count

    Change from baseline in CD4⁺ and CD8⁺ T-cell counts

    Time frame: From enrollment to the end of treatment at 24 weeks

  3. Maximum Observed Concentration (Cmax)

    Maximum Observed Concentration (Cmax) of CAR-NK

    Time frame: From enrollment to the end of treatment at 24 weeks

  4. Area Under the Curve (AUCtau)

    Area Under the Curve (AUCtau) during the dosing intervals for CAR-NK

    Time frame: From enrollment to the end of treatment at 24 weeks

  5. Time to Cmax (Tmax)

    Time to Cmax (Tmax) of CAR-NK

    Time frame: From enrollment to the end of treatment at 24 weeks

  6. Observed Concentration (Ctrough)

    Observed Concentration (Ctrough) at the end of the dosing intervals for CAR-NK

    Time frame: From enrollment to the end of treatment at 24 weeks

  7. Evaluation of the Cytokine Profile

    Assessment of blood cytokine levels before and after treatment, including but not limited to the following pro-inflammatory and immunoregulatory cytokines: IL-6, TNFα, IL-10, and IFNγ

    Time frame: From enrollment to the end of treatment at 24 weeks

  8. Half-life (t1/2)

    Half-life (t1/2) of CAR-NK following the last dose

    Time frame: From enrollment to the end of treatment at 24 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Participant Privacy and Confidentiality: Although data would be de-identified prior to sharing, the IPD encompass detailed clinical, virologic, and immunologic parameters. Given the specific sensitivities associated with the HIV-infected population and the nature of the medical information, a residual risk of re-identification through the triangulation of indirect identifiers persists. Public sharing of IPD may therefore contravene data protection regulations and the privacy assurances stipulated in the participant informed consent documentation. Limitations of Informed Consent Scope: The informed consent form executed for this study does not explicitly authorize the disclosure of participant-level raw data to third parties or its deposition in public data repositories. The investigators are bound by legal and ethical obligations to utilize the data solely within the parameters approved in the study protocol and the corresponding informed consent.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for May 2027, 12 months later.

Of 28 phase 1/2 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 24. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2026
First posted
May 11, 2026
StartEst.
May 1, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
Dec 30, 2027
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07577986
Collaborators
Hangzhou Suxi Biopharmaceutical Co., Ltd.
Responsible party
Biao Zhu (Chief Physician, First Affiliated Hospital of Zhejiang University) — Principal investigator
First posted
May 11, 2026
Start date
May 1, 2026 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
May 11, 2026

Study contacts

Biao Zhu
Contact
zhubiao1207@zju.edu.cn
+86 87236437

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion